Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
HIF-2α inhibitor (investigational)
Casdatifan
· CASD
An investigational next-generation HIF-2α inhibitor for clear-cell RCC, with class-based anemia/edema effects under study.
MildHIF-2α inhibitor (investigational) · approved 2026
Clear-cell renal cell carcinoma (investigational)
Signature kidney injury
Prerenal / Hemodynamic AKI
Renal-specific data are not established. By analogy to the first-in-class HIF-2α inhibitor belzutifan, expected on-target effects include anemia (belzutifan: ~27-90% across trials) and hypoxia, plus possible fluid retention/edema; these are class effects rather than direct nephron injury. No casdatifan-specific renal incidence is published.
Source: McKay et al., Am Soc Clin Oncol Educ Book 2025
Mechanism of kidney injury
Predicted/indirect: HIF-2α inhibition reduces erythropoietin (on-target anemia) and VEGF signaling, with possible hemodynamic and fluid-balance effects. Any AKI is anticipated to be prerenal/hemodynamic rather than a structural tubular lesion. When combined with VEGFR-TKIs (e.g., cabozantinib), the TKI partner contributes hypertension and glomerular (podocyte VEGF-deprivation) proteinuria — the more renally relevant combination effect.
Clinical presentation
Anemia and hypoxia as the recognized class effects; if present, modest creatinine changes with bland sediment; in combination regimens, watch for TKI-driven hypertension and proteinuria.
Onset
Not established; class anemia/hypoxia effects emerge during ongoing therapy.
Reversibility
Variable
Anticancer mechanism
Oral, potent, selective hypoxia-inducible factor-2α (HIF-2α) inhibitor that allosterically prevents HIF-2α/ARNT (HIF-1β) heterodimerization. HIF-2α is a key oncogenic driver in VHL-deficient clear-cell renal cell carcinoma (ccRCC); blocking it suppresses VEGF-, cyclin-D1- and EPO-driven programs. In development (ARC-20 platform; phase 3 with cabozantinib, NCT07011719); not yet approved.
Management
Supportive; manage anemia and hypoxia per class experience, treat hypertension/proteinuria if a TKI partner is used, and correct prerenal factors. No drug-specific renal therapy is defined.
Risk factors
- Pre-existing CKD (common in RCC after nephrectomy / solitary kidney)
- Combination with VEGFR-TKIs (additive hypertension/proteinuria)
- Baseline anemia
Prevention
- Monitor hemoglobin, oxygen saturation, creatinine and (in combinations) blood pressure and proteinuria
- Account for solitary kidney / reduced nephron mass common in RCC
Note · INVESTIGATIONAL (yearApproved set to 2026 as a near estimate per contract). No renal-specific literature; framing is conservative HIF-2α-class reasoning by analogy to belzutifan. Treat as hypothesis-level.
Clinical depth
Renal dose adjustment
Not established (investigational). HIF-2α inhibitors are hepatically metabolized; meaningful renal-clearance dependence is not expected, but formal renal-impairment dosing has not been published. Many ccRCC patients have reduced nephron mass after nephrectomy, which is relevant to baseline GFR interpretation.
Dialyzability & ESKD dosing
Not characterized; a protein-bound, hepatically cleared small molecule is unlikely to be appreciably dialyzed. No ESKD dosing data.
Differential diagnosis
In combination regimens, attribute hypertension/proteinuria to the VEGFR-TKI partner (podocyte/glomerular effect) and anemia/hypoxia to the HIF-2α agent; distinguish prerenal creatinine changes from any TKI-related TMA/glomerular injury.
Monitoring
- Hemoglobin and oxygen saturation (on-target anemia/hypoxia)
- Creatinine and, in combinations, blood pressure and urine protein/ACR
- Volume status/edema
Key trials & series
- ARC-20 ccRCC platform study (monotherapy and with cabozantinib)
- Phase 3 casdatifan + cabozantinib (NCT07011719)
Clinical pearls
- On-target anemia and hypoxia are the hallmark HIF-2α class effects (EPO/VEGF suppression), not direct nephrotoxicity.
- The renally important combination effect is the VEGFR-TKI partner's hypertension and proteinuria — monitor BP and urine protein.
- A drug that treats kidney cancer while its own renal-safety profile is still being defined — reason from belzutifan by analogy.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkEmerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.McKay RR et al. · Am Soc Clin Oncol Educ Book 2025 · PMID 40198857Reviews casdatifan among next-generation HIF-2α inhibitors and the belzutifan class, framing the expected anemia/hypoxia class effects.PMIDDiscovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α.Mailyan AK et al. · J Med Chem 2026 · PMID 42246926Discovery/pharmacology of casdatifan, including its ARC-20 ccRCC and phase 3 cabozantinib-combination context.LandmarkBelzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.Jonasch E et al. · N Engl J Med 2021 · PMID 34818478Class-defining HIF-2α inhibitor trial establishing anemia (90%) and hypoxia as the dominant on-target adverse events — the analogy for casdatifan's expected profile.PMIDInhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.Choueiri TK et al. · Nat Med 2021 · PMID 33888901First-in-human HIF-2α inhibitor data linking erythropoietin suppression to dose and documenting anemia/hypoxia as key class toxicities.
Related agents
Other agents sharing the same signature kidney injury.